Disposition of 1727 shares by Dinesh Patel of Protagonist Therapeutics at 21.58 subject to Rule 16b-3
| PTGX Stock | USD 36.82 0.28 0.77% |
Slightly above 53% of Protagonist Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Protagonist Therapeutics suggests that many traders are impartial. Protagonist Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Protagonist Therapeutics' earnings reports, geopolitical events, and overall market trends.
Protagonist |
Filed transaction by Protagonist Therapeutics Director, Officer: President And Ceo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Protagonist Therapeutics Fundamental Analysis
We analyze Protagonist Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protagonist Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protagonist Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
Protagonist Therapeutics is currently under evaluation in target price category among its peers.
Protagonist Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Protagonist Therapeutics stock to make a market-neutral strategy. Peer analysis of Protagonist Therapeutics could also be used in its relative valuation, which is a method of valuing Protagonist Therapeutics by comparing valuation metrics with similar companies.
Peers
Protagonist Therapeutics Related Equities
| REPL | Replimune | 16.86 | ||||
| XFOR | X4 Pharmaceuticals | 10.87 | ||||
| VTYX | Ventyx Biosciences | 6.88 | ||||
| RNA | Avidity Biosciences | 6.64 | ||||
| AKRO | Akero Therapeutics | 4.71 | ||||
| SNDX | Syndax Pharmaceuticals | 4.51 | ||||
| RLAY | Relay Therapeutics | 4.48 | ||||
| IDYA | Ideaya Biosciences | 4.37 | ||||
| ARVN | Arvinas | 2.88 | ||||
| ABOS | Acumen Pharmaceuticals | 2.48 | ||||
| BDTX | Black Diamond | 1.82 | ||||
| DAWN | Day One | 1.13 | ||||
| KURA | Kura Oncology | 1.11 | ||||
| MRUS | Merus BV | 0.74 | ||||
| HOOK | Hookipa Pharma | 0.52 | ||||
| RVMD | Revolution Medicines | 0.32 | ||||
| STOK | Stoke Therapeutics | 1.06 | ||||
| PLRX | Pliant Therapeutics | 1.25 | ||||
| TERN | Terns Pharmaceuticals | 1.56 | ||||
| VRNA | Verona Pharma | 3.26 |
Additional Tools for Protagonist Stock Analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.